← Eichor
Study identifier: NCT07279688 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

Condition: Polymyalgia Rheumatica (PMR)  ·  Sponsor: University Hospital, Brest

PhasePhase 3
Planned participants140
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

Polymyalgia rheumatic (PMR) is an inflammatory rheumatic disease affecting the elderly. The diagnosis is based on established ACR/EULAR classification criteria. The activity of the disease is evaluated using the PMR-AS, a disease activity score based on morning stiffness, ability to elevate the upper limbs, physician's global disease assessment and pain assessment measured by the patient using VAS, and the C-reactive protein (CRP) level. The PMR-AS-CRP (PMR-AS) is considered as relevant to define disease activity (low activity \<7; moderate activity 7 to 17; high activity \>17), flare (\>10), remission (\<1.5), but also to decide if treatment has to be decreased, unchanged or increased (PMR-AS \<10: decrease, PMR-AS \>20 increase, 10≤ PMR-AS ≤20: stable dose) \[10-12\]. Long term low-dose glucocorticoid (GCs) (prednisone or prednisolone started at 12.5 to 25 mg/day progressively tapered) is the mainstay of the treatment. But comorbidities in PMR are due to GCs and 30% of the patients underwent a relapse when tapering GCs. Today, the physicians do not know what is the best duration and the best dosage of GCs. The international recommendation suggests to start prednisone at a dose between 12.5 to 25 mg, to be at 10 mg at 1 or 2 months, and then to decrease slowly. The treatment is generally ordered for 6-18 months but it is possible to try a shorter treatment duration when patients have been previously treated with GCs or in case of comorbidities. The TENOR study, a phase 2…

This description comes directly from the study's public registry record.

Talk to the study team

Alain SARAUX, Pr  ·  +33298223333  ·  alain.saraux@chu-brest.fr

Always discuss trial participation with your own doctor first.

Locations (22)

VIDAL FrançoisAix-en-Provence, FranceRecruiting
LEGRAND Jean-LouisArras, FranceNot Yet Recruiting
Besançon-CICBesançon, FranceRecruiting
PRATI ClémentBesançon, FranceRecruiting
CHU de Bordeaux PellegrinBordeaux, FranceNot Yet Recruiting
Dr Alain SARAUXBrest, FranceRecruiting
RAT Anne-ChristineCaen, FranceRecruiting
LESKE CharlesCholet, FranceRecruiting
TOURNADRE AnneClermont-Ferrand, FranceNot Yet Recruiting
RAMON AndréDijon, FranceNot Yet Recruiting
APHP - Kremlin-BicêtreLe Kremlin-Bicêtre, FranceNot Yet Recruiting
DIREZ GuillaumeLe Mans, FranceRecruiting

+ 10 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07279688